A non-invasive magnetic imaging (MRI) tool is being developed by The University of Manchester spinout company Bioxydyn. It has the potential to improve the treatment of lung conditions such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis and emphysema.
The diagnostic imaging technologies has the potential to change the way lung disease is diagnosed and monitored by providing non-invasive regional assessments of lung ventilation/perfusion ratio (V/Q) and measuring changes in pulmonary vascular function. The company is also developing MRI based oncology tools for quantifying tumour oxygenation and oxygen metabolism. It is hoped that the provision of non-invasive characterisation of the oxygenation status of tumours will aid therapeutic decision making and provide additional information for assessing the response of tumours to intervention.
